Skip to main content
. 2023 Jun 2;30(6):5425–5447. doi: 10.3390/curroncol30060411

Figure 4.

Figure 4

Incidence of most common adverse reactions as per product monograph in patients with advanced breast cancer receiving CDK4/6i + nonsteroidal AI.